From Wikipedia, the free encyclopedia
Jump to: navigation, search
Ranimustine (Haworth).svg
Clinical data
Trade names Cymerin
AHFS/Drugs.com International Drug Names
Routes of
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Synonyms 1-(2-chloroethyl)-1-nitroso-3-([(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-methoxyoxan-2-yl]methyl)urea
CAS Number
PubChem CID
Chemical and physical data
Formula C10H18ClN3O7
Molar mass 327.71 g/mol
3D model (Jmol)

Ranimustine (INN, marketed under the tradename Cymerin; also known as MCNU) is a nitrosourea alkylating agent approved in Japan for the treatment of chronic myelogenous leukemia[1] and polycythemia vera.[2]

It has never been filed for FDA evaluation in the United States, where it is not marketed.


  1. ^ Kitajima K, Adachi T, Takahashi I, et al. (November 1989). "[Chemotherapy of chronic myelogenous leukemia--VP(M) regimen initiated during its chronic phase, and evaluation of MCNU in the phase of blastic crisis]". Gan To Kagaku Ryoho (in Japanese). 16 (11): 3573–9. PMID 2817908. 
  2. ^ Nagai M, Tasaka T, Kamano H, et al. (December 1988). "[Therapeutic effect of ranimustine (MCNU) on essential thrombocythemia and polycythemia vera]". Gan To Kagaku Ryoho (in Japanese). 15 (12): 3267–70. PMID 3196045.